A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Back to Search
Print
Bookmark Trial

NCT01858389

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Tower Hematology Oncology Medical Group
Beverly Hills, California, 90211, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of histologically confirmed, advanced NSCLC (stage IIIB/IV).

- Evidence of T790M mutation to enroll in Cohort A.

- Evidence of measurable disease by radiographic technique.

- Adequate organ function.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with T790M mutation who stopped any prior EGFR-directed therapy without
evidence of disease progression.


- Symptomatic brain metastases.


- Uncontrolled or significant cardiovascular disease.


- Pregnant or breastfeeding.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
NCT03915951
  1. Norwich, Connecticut
  2. Fort Myers, Florida
  3. Saint Petersburg, Florida
  4. Tallahassee, Florida
  5. Boston, Massachusetts
  6. Kansas City, Missouri
  7. Saint Louis, Missouri
  8. Hackensack, New Jersey
  9. Bronx, New York
  10. New York, New York
  11. Durham, North Carolina
  12. Chattanooga, Tennessee
  13. Nashville, Tennessee
  14. Houston, Texas
  15. Barcelona, Cataluna
  16. Barcelona, Cataluna
  17. Córdoba, Cordoba
  18. Majadahonda, Madrid
  19. Málaga, Malage
  20. Madrid,
  21. Madrid,
  22. Sevilla,
  23. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
NCT01360554
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Florence, Alabama
  5. Mobile, Alabama
  6. Mobile, Alabama
  7. Muscle Shoals, Alabama
  8. Chandler, Arizona
  9. Chandler, Arizona
  10. Gilbert, Arizona
  11. Mesa, Arizona
  12. Mesa, Arizona
  13. Fayetteville, Arkansas
  14. Rogers, Arkansas
  15. Alhambra, California
  16. Alhambra, California
  17. Duarte, California
  18. Fullerton, California
  19. Los Angeles, California
  20. Los Angeles, California
  21. Los Angeles, California
  22. Los Angeles, California
  23. Los Angeles, California
  24. Los Angeles, California
  25. Los Angeles, California
  26. Los Angeles, California
  27. Los Angeles, California
  28. Los Angeles, California
  29. Pasadena, California
  30. Pasadena, California
  31. Redondo Beach, California
  32. Santa Maria, California
  33. Santa Monica, California
  34. Santa Monica, California
  35. Santa Monica, California
  36. South Pasadena, California
  37. Valencia, California
  38. Westlake Village, California
  39. Norwalk, Connecticut
  40. Orlando, Florida
  41. Orlando, Florida
  42. Orlando, Florida
  43. Orlando, Florida
  44. Port Saint Lucie, Florida
  45. Atlanta, Georgia
  46. Atlanta, Georgia
  47. Atlanta, Georgia
  48. Atlanta, Georgia
  49. Austell, Georgia
  50. Carrollton, Georgia
  51. Cartersville, Georgia
  52. Columbus, Georgia
  53. Decatur, Georgia
  54. Decatur, Georgia
  55. Decatur, Georgia
  56. Douglasville, Georgia
  57. Duluth, Georgia
  58. Gainesville, Georgia
  59. Gainesville, Georgia
  60. Gainesville, Georgia
  61. Lawrenceville, Georgia
  62. Marietta, Georgia
  63. Snellville, Georgia
  64. Arlington Heights, Illinois
  65. Harvey, Illinois
  66. Harvey, Illinois
  67. Harvey, Illinois
  68. Niles, Illinois
  69. Tinley Park, Illinois
  70. Evansville, Indiana
  71. Munster, Indiana
  72. Waterloo, Iowa
  73. Hazard, Kentucky
  74. Louisville, Kentucky
  75. Louisville, Kentucky
  76. Louisville, Kentucky
  77. Detroit, Michigan
  78. Farmington Hills, Michigan
  79. Starkville, Mississippi
  80. Tupelo, Mississippi
  81. Creve Coeur, Missouri
  82. Saint Louis, Missouri
  83. Saint Louis, Missouri
  84. Saint Peters, Missouri
  85. Lebanon, New Hampshire
  86. Denville, New Jersey
  87. Stony Brook, New York
  88. Hickory, North Carolina
  89. Lenoir, North Carolina
  90. Norman, Oklahoma
  91. Oklahoma City, Oklahoma
  92. Oklahoma City, Oklahoma
  93. Corvallis, Oregon
  94. Corvallis, Oregon
  95. Corvallis, Oregon
  96. Lincoln City, Oregon
  97. Newport, Oregon
  98. Sayre, Pennsylvania
  99. Sayre, Pennsylvania
  100. Longview, Texas
  101. Tyler, Texas
  102. Waco, Texas
  103. Kennewick, Washington
  104. Richland, Washington
  105. Richland, Washington
  106. Seattle, Washington
  107. Seattle, Washington
  108. Vienna,
  109. Brussels,
  110. Brussels,
  111. Charleroi,
  112. Mons,
  113. Roeselare,
  114. Nanning, Guangxi
  115. Wuhan, Hubei
  116. Changchun, Jilin
  117. Chengdu, Sichuan
  118. Shanghai,
  119. Aalborg,
  120. Helsinki,
  121. Pori,
  122. Dijon,
  123. Grenoble cedex 09,
  124. Paris,
  125. Poitiers Cedex,
  126. Saint Herblain cedex,
  127. Aachen,
  128. Gauting,
  129. Immenhausen,
  130. Mainz,
  131. Moers,
  132. Larissa, Thessaly
  133. Athens,
  134. Heraklion,
  135. Budapest,
  136. Debrecen,
  137. Farkasgyepu,
  138. Gyula,
  139. Nyiregyhaza,
  140. Zalaegerszeg-Pozva,
  141. Ahmedabad, Gujarat
  142. Bangalore, Karnataka
  143. Mumbai, Maharashtra
  144. Pune, Maharastra
  145. Dublin, Leinster
  146. Dublin, Leinster
  147. Dublin,
  148. Waterford,
  149. Nagoya, Aichi
  150. Kashiwa, Chiba
  151. Matsuyama-city, Ehime
  152. Asahikawa, Hokkaido
  153. Akashi, Hyogo
  154. Kanazawa city, Ishikawa
  155. Yokohama, Kanagawa
  156. Sendai, Miyagi
  157. Kurashiki, Okayama
  158. Okayama-city, Okayama
  159. Sakai-Shi, Osaka-fu
  160. Osaka-city, Osaka
  161. Osakasayama-shi, Osaka
  162. Sunto-gun, Shizuoka
  163. Chuo-Ku, Tokyo
  164. Ube-shi, Yamaguchi
  165. Fukuoka,
  166. Fukuoka,
  167. Fukuoka,
  168. Koto-ku, Tokyo,
  169. Seoul,
  170. Seoul,
  171. Seoul,
  172. Oaxaca,
  173. Otwock, Mazowieckie
  174. Otwock, Mazowieckie
  175. Warsaw, Mazowieckie
  176. Warsaw, Mazowieckie
  177. Krasnodar, Krasnodarskij Kraj
  178. Sochi, Krasnodarskij Kraj
  179. Pyatigorsk, Stavropolskij Kraj
  180. Pyatigorsk,
  181. Saint-Petersburg,
  182. Saint-Petersburg,
  183. Saint-Petersburg,
  184. Saint-Petersburg,
  185. Saint-Petersburg,
  186. Saint-Petersburg,
  187. Saint-Petersburg,
  188. Samara,
  189. Bratislava,
  190. Nitra,
  191. Nove Zamky,
  192. Parktown,Johannesburg, Gauteng
  193. Kraaifontein, Western Cape
  194. Bloemfontein,
  195. Port Elizabeth,
  196. Elche, Alicante
  197. Badalona, Barcelona
  198. Castellón, Castellon
  199. Barcelona,
  200. Barcelona,
  201. Barcelona,
  202. Barcelona,
  203. Barcelona,
  204. Barcelona,
  205. Castellon,
  206. Madrid,
  207. Madrid,
  208. Madrid,
  209. Sevilla,
  210. Karlstad,
  211. Stockholm,
  212. Aarau,
  213. Bellinzona,
  214. Geneve 14,
  215. Locarno,
  216. St. Gallen,
  217. Maidstone, Kent
  218. Wolverhampton, West Midlands
  219. Edmonton,
  220. Leicester,
  221. London,
  222. Manchester,
  223. Manchester,
  224. Manchester,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerStudy Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
NCT00372775
  1. Norwalk, Connecticut
  2. Cocoa Beach, Florida
  3. Merritt Island, Florida
  4. Titusville, Florida
  5. Creve Coeur, Missouri
  6. St. Louis, Missouri
  7. St. Louis, Missouri
  8. St. Peters, Missouri
  9. Basking Ridge, New Jersey
  10. Commack, New York
  11. New York, New York
  12. Sayre, Pennsylvania
  13. Austin, Texas
  14. Austin, Texas
  15. Austin, Texas
  16. Austin, Texas
  17. Round Rock, Texas
  18. Pessac, Be1 04495
  19. Marseille Cedex 09,
  20. Saint-Priest en Jarez Cedex,
  21. Toulouse cedex 9,
  22. Bologna,
  23. Genova,
  24. Orbassano (TO),
  25. Roma,
  26. Madrid,
  27. Valencia,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerA Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
NCT00769067
  1. Muscle Shoals, Alabama
  2. Montebello, California
  3. Bridgeport, Connecticut
  4. Norwalk, Connecticut
  5. Waterbury, Connecticut
  6. Atlanta, Georgia
  7. Atlanta, Georgia
  8. Atlanta, Georgia
  9. Atlanta, Georgia
  10. Atlanta, Georgia
  11. Augusta, Georgia
  12. Augusta, Georgia
  13. Columbus, Georgia
  14. Decatur, Georgia
  15. Gainesville, Georgia
  16. Macon, Georgia
  17. Marietta, Georgia
  18. Warner Robins, Georgia
  19. Post Falls, Idaho
  20. Post Falls, Idaho
  21. Zion, Illinois
  22. Bethesda, Maryland
  23. Rockville, Maryland
  24. Minneapolis, Minnesota
  25. Memphis, Tennessee
  26. Clarksburg, West Virginia
  27. Camperdown, New South Wales
  28. Fitzroy, Victoria
  29. Geelong, Victoria
  30. Wodonga, Victoria
  31. Porto Alegre, RS
  32. Porto Alegre, RS
  33. Barretos, SP
  34. Sao Paulo, SP
  35. Vancouver, British Columbia
  36. Barrie, Ontario
  37. Oshawa, Ontario
  38. Ottawa, Ontario
  39. Shatin, New Territories
  40. Tuen Mun, New Territories
  41. Seoul,
  42. Seoul,
  43. Seoul,
  44. Chrzanow,
  45. Krakow,
  46. Krakow,
  47. Krakow,
  48. Warsaw,
  49. Warszawa,
  50. Ponce,
  51. Singapore,
  52. Badalona, Barcelona
  53. Palma de Mallorca, Islas Baleares
  54. Barakaldo, Vizcaya
  55. La Coruña,
  56. Taipei,
  57. Taipei,
  58. Manchester,
  59. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Official Title  ICMJE Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced Nsclc
Brief Summary This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of patients, those whose tumor has a documented T790M mutation, and those without this mutation. All patients will receive repeated cycles of dacomitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Non-small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Dacomitinib
    Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
  • Drug: Dacomitinib
    Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
Study Arms  ICMJE
  • Experimental: Cohort A
    Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
    Intervention: Drug: Dacomitinib
  • Experimental: Cohort B
    Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
    Intervention: Drug: Dacomitinib
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 17, 2017)		41
Original Estimated Enrollment  ICMJE
 (submitted: May 16, 2013)		35
Actual Study Completion Date  ICMJE September 2015
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Evidence of histologically confirmed, advanced NSCLC (stage IIIB/IV).
  • Evidence of T790M mutation to enroll in Cohort A.
  • Evidence of measurable disease by radiographic technique.
  • Adequate organ function.

Exclusion Criteria:

  • Patients with T790M mutation who stopped any prior EGFR-directed therapy without evidence of disease progression.
  • Symptomatic brain metastases.
  • Uncontrolled or significant cardiovascular disease.
  • Pregnant or breastfeeding.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Korea, Republic of,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01858389
Other Study ID Numbers  ICMJE A7471047
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP